TCR2 Therapeutics Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 40.4 million compared to USD 29.12 million a year ago. Basic loss per share from continuing operations was USD 1.03 compared to USD 0.76 a year ago.
TCR2 Therapeutics Inc.
Equities
TCRR
US87808K1060
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |